David Bredt
Chief Scientific Officer at Rapport Therapeutics, Inc. (RAPP)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $1.4M
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Feb 19SEC | RAPPRapport Therapeutics, Inc. | Sell Plan | 900394,675 held (−0%) | $28.02 | $25K | +9.4% |
| Feb 19SEC | RAPPRapport Therapeutics, Inc. | Sell Plan | 5,400389,275 held (−1%) | $28.95 | $156K | +5.9% |
| Feb 19SEC | RAPPRapport Therapeutics, Inc. | Sell Plan | 2,200387,075 held (−1%) | $29.59 | $65K | +3.6% |
| Jan 16SEC | RAPPRapport Therapeutics, Inc. | Sell Plan | 8,300395,775 held (−2%) | $26.83 | $223K | +14.2% |
| Jan 16SEC | RAPPRapport Therapeutics, Inc. | Sell Plan | 200395,575 held (−0%) | $27.40 | $5K | +11.9% |
| Jan 5SEC | RAPPRapport Therapeutics, Inc. | Sell | 6,567404,075 held (−2%) | $30.05 | $197K | +2.0% |
| Dec 16SEC | RAPPRapport Therapeutics, Inc. | Sell Plan | 7,704393,438 held (−2%) | $29.95 | $231K | +2.3% |
| Dec 16SEC | RAPPRapport Therapeutics, Inc. | Sell Plan | 796392,642 held (−0%) | $30.68 | $24K | -0.1% |
| Nov 18SEC | RAPPRapport Therapeutics, Inc. | Sell Plan | 3,156406,486 held (−1%) | $24.84 | $78K | +23.4% |
| Nov 18SEC | RAPPRapport Therapeutics, Inc. | Sell Plan | 5,344401,142 held (−1%) | $25.39 | $136K | +20.7% |
| Oct 16SEC | RAPPRapport Therapeutics, Inc. | Sell Plan | 7,418410,724 held (−2%) | $25.73 | $191K | +19.1% |
| Oct 16SEC | RAPPRapport Therapeutics, Inc. | Sell Plan | 1,082409,642 held (−0%) | $26.16 | $28K | +17.2% |
- Sell
Chief Scientific Officer David Bredt sold $25K of RAPP at $28.02 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Scientific Officer David Bredt sold $156K of RAPP at $28.95 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Scientific Officer David Bredt sold $65K of RAPP at $29.59 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Scientific Officer David Bredt sold $223K of RAPP at $26.83 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Scientific Officer David Bredt sold $5K of RAPP at $27.40 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Scientific Officer David Bredt sold $231K of RAPP at $29.95 — pre-scheduled 10b5-1 plan sale.